{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:48:35Z","timestamp":1790423315097,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG1104"],"award-info":[{"award-number":["01KG1104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Chronic kidney disease (CKD) seriously affects the well-being and shortens the life expectancy of children and adolescents, but its progression is challenging to predict. Therefore, there is an urgent need for biomarkers that can identify children at risk of faster CKD progression. Alport syndrome (AS) is the most common monogenetic glomerular kidney disease. Urinary Dickkopf-related protein 3\n                      <jats:bold>(<\/jats:bold>\n                      DKK3) is associated with a decline in estimated glomerular filtration rate (eGFR) in adults and children with advanced CKD. However, its potential for early detection of CKD and its prognostic value in children with AS remain unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Urine samples from 49 children enrolled in the EARLY PRO-TECT Alport trial were analyzed to evaluate whether DKK3 could identify children with AS to be at risk for faster CKD progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DKK3 levels in patients with AS were higher than those of healthy individuals reported in the literature. DKK3 levels were more elevated in patients with later stages of AS. Furthermore, children who were not treated with renin angiotensin system inhibitors (RASi) had higher DKK3 levels than treated children. Children with above-average DKK3 levels were more likely to have increased albuminuria after 2\u00a0years of follow-up than children with below-average DKK3 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Urinary DKK3 is significantly elevated in children at early stages of AS. There was a potential association between higher DKK3 levels, worsening albuminuria, and a decline in kidney function. These findings suggest that DKK3 may be a prognostic marker for predicting the risk of kidney damage in children with AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-025-06696-3","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:53:26Z","timestamp":1738688006000},"page":"2205-2213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Urinary Dickkopf-related protein 3 as a novel biomarker for kidney function decline in children with Alport syndrome"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2021-9255","authenticated-orcid":false,"given":"Jan","family":"Boeckhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"T\u00f6nshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Latta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Fehrenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baerbel","family":"Lange-Sperandio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kettwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"John-Kroegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Gellermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Galiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Jami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gry Helene","family":"Dihazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hafke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max C.","family":"Liebau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Wallbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"6696_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.kint.2016.02.016","volume":"89","author":"NC Chesnaye","year":"2016","unstructured":"Chesnaye NC, Schaefer F, Groothoff JW, Bonthuis M, Reusz G, Heaf JG, Lewis M, Maurer E, Paripovi\u0107 D, Zagozdzon I, van Stralen KJ, Jager KJ (2016) Mortality risk in European children with end-stage renal disease on dialysis. Kidney Int 89:1355\u20131362. https:\/\/doi.org\/10.1016\/j.kint.2016.02.016","journal-title":"Kidney Int"},{"key":"6696_CR2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00467-006-0081-y","volume":"21","author":"SL Goldstein","year":"2006","unstructured":"Goldstein SL, Graham N, Burwinkle T, Warady B, Farrah R, Varni JW (2006) Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol 21:846\u2013850. https:\/\/doi.org\/10.1007\/s00467-006-0081-y","journal-title":"Pediatr Nephrol"},{"key":"6696_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S2352-4642(23)00049-4","volume":"7","author":"T Speer","year":"2023","unstructured":"Speer T, Schunk SJ, Sarakpi T, Schmit D, Wagner M, Arnold L, Zewinger S, Azukaitis K, Bayazit A, Obrycki L, Bulut IK, Duzova A, Doyon A, Ranchin B, Caliskan S, Harambat J, Yilmaz A, Alpay H, Lugani F, Balat A, Arbeiter K, Longo G, Melk A, Querfeld U, W\u00fchl E, Mehls O, Fliser D, Schaefer F (2023) Urinary DKK3 as a biomarker for short-term kidney function decline in children with chronic kidney disease: an observational cohort study. Lancet Child Adolesc Health 7:405\u2013414. https:\/\/doi.org\/10.1016\/S2352-4642(23)00049-4","journal-title":"Lancet Child Adolesc Health"},{"key":"6696_CR4","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.ekir.2022.08.021","volume":"7","author":"JT Gibson","year":"2022","unstructured":"Gibson JT, de Gooyer M, Huang M, Savige J (2022) A systematic review of pathogenic COL4A5 variants and proteinuria in women and girls with X-linked Alport syndrome. Kidney Int Rep 7:2454\u20132461. https:\/\/doi.org\/10.1016\/j.ekir.2022.08.021","journal-title":"Kidney Int Rep"},{"key":"6696_CR5","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/genes14091686","volume":"14","author":"C Deltas","year":"2023","unstructured":"Deltas C, Papagregoriou G, Louka SF, Malatras A, Flinter F, Gale DP, Gear S, Gross O, Hoefele J, Lennon R, Miner JH, Renieri A, Savige J, Turner AN (2023) Genetic modifiers of mendelian monogenic collagen IV nephropathies in humans and mice. Genes 14:1686. https:\/\/doi.org\/10.3390\/genes14091686","journal-title":"Genes"},{"key":"6696_CR6","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","volume":"348","author":"BG Hudson","year":"2003","unstructured":"Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG (2003) Alport\u2019s syndrome, goodpasture\u2019s syndrome, and type IV collagen. N Engl J Med 348:2543\u20132556. https:\/\/doi.org\/10.1056\/NEJMra022296","journal-title":"N Engl J Med"},{"key":"6696_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrneph.2012.259","volume":"9","author":"J Kruegel","year":"2013","unstructured":"Kruegel J, Rubel D, Gross O (2013) Alport syndrome\u2014insights from basic and clinical research. Nat Rev Nephrol 9:170\u2013178. https:\/\/doi.org\/10.1038\/nrneph.2012.259","journal-title":"Nat Rev Nephrol"},{"key":"6696_CR8","doi-asserted-by":"publisher","first-page":"F120","DOI":"10.1152\/ajprenal.00456.2015","volume":"311","author":"G Jarad","year":"2016","unstructured":"Jarad G, Knutsen RH, Mecham RP, Miner JH (2016) Albumin contributes to kidney disease progression in Alport syndrome. Am J Physiol Renal Physiol 311:F120\u2013F130. https:\/\/doi.org\/10.1152\/ajprenal.00456.2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"6696_CR9","first-page":"1157","volume":"58","author":"DF Barker","year":"1996","unstructured":"Barker DF, Pruchno CJ, Jiang X, Atkin CL, Stone EM, Denison JC, Fain PR, Gregory MC (1996) A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. Am J Hum Genet 58:1157\u20131165","journal-title":"Am J Hum Genet"},{"key":"6696_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/life10120360","volume":"10","author":"J Boeckhaus","year":"2020","unstructured":"Boeckhaus J, Strenzke N, Storz C, Gross O (2020) Characterization of sensorineural hearing loss in children with Alport syndrome. Life (Basel) 10:360. https:\/\/doi.org\/10.3390\/life10120360","journal-title":"Life (Basel)"},{"key":"6696_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s004670050804","volume":"14","author":"CE Kashtan","year":"2000","unstructured":"Kashtan CE (2000) Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis. Pediatr Nephrol 14:502\u2013512. https:\/\/doi.org\/10.1007\/s004670050804","journal-title":"Pediatr Nephrol"},{"key":"6696_CR12","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s00467-021-05040-9","volume":"36","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, B\u00f6ckhaus J, Wang F, Wang S, Rubel D, Gross O, Ding J (2021) Genotype\u2013phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol 36:2719\u20132730. https:\/\/doi.org\/10.1007\/s00467-021-05040-9","journal-title":"Pediatr Nephrol"},{"key":"6696_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00467-014-2797-4","volume":"29","author":"M Oka","year":"2014","unstructured":"Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, Morisada N, Yan K, Matsuo M, Yoshikawa N, Vorechovsky I, Iijima K (2014) Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol 29:1535\u20131544. https:\/\/doi.org\/10.1007\/s00467-014-2797-4","journal-title":"Pediatr Nephrol"},{"key":"6696_CR14","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/ejhg.2014.254","volume":"23","author":"JM Hertz","year":"2015","unstructured":"Hertz JM, Thomassen M, Storey H, Flinter F (2015) Clinical utility gene card for: Alport syndrome \u2013 update 2014. Eur J Hum Genet 23:1269\u20131269. https:\/\/doi.org\/10.1038\/ejhg.2014.254","journal-title":"Eur J Hum Genet"},{"key":"6696_CR15","doi-asserted-by":"publisher","first-page":"865034","DOI":"10.3389\/fmed.2022.865034","volume":"9","author":"J Savige","year":"2022","unstructured":"Savige J, Huang M, Croos Dabrera MS, Shukla K, Gibson J (2022) Genotype-phenotype correlations for pathogenic COL4A3\u2013COL4A5 variants in X-linked, autosomal recessive, and autosomal dominant Alport syndrome. Front Med 9:865034. https:\/\/doi.org\/10.3389\/fmed.2022.865034","journal-title":"Front Med"},{"key":"6696_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MNH.0000000000000983","volume":"33","author":"P Puapatanakul","year":"2024","unstructured":"Puapatanakul P, Miner JH (2024) Alport syndrome and Alport kidney diseases \u2013 elucidating the disease spectrum. Curr Opin Nephrol Hypertens 33:283. https:\/\/doi.org\/10.1097\/MNH.0000000000000983","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"6696_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","volume":"36","author":"CE Kashtan","year":"2021","unstructured":"Kashtan CE, Gross O (2021) Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults\u2013an update for 2020. Pediatr Nephrol 36:711\u2013719. https:\/\/doi.org\/10.1007\/s00467-020-04819-6","journal-title":"Pediatr Nephrol"},{"key":"6696_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cge.13861","volume":"99","author":"J Boeckhaus","year":"2021","unstructured":"Boeckhaus J, Hoefele J, Riedhammer KM, T\u00f6nshoff B, Ehren R, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Kettwig M, Hoyer P, Staude H, Konrad M, John U, Gellermann J, Hoppe B, Galiano M, Gessner M, Pohl M, Bergmann C, Friede T, Gross O (2021) Precise variant interpretation, phenotype ascertainment, and genotype\u2013phenotype correlation of children in the early pro-tect Alport trial. Clin Genet 99:143\u2013156. https:\/\/doi.org\/10.1111\/cge.13861","journal-title":"Clin Genet"},{"key":"6696_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","volume":"81","author":"O Gross","year":"2012","unstructured":"Gross O, Licht C, Anders HJ, Hoppe B, Beck B, T\u00f6nshoff B, H\u00f6cker B, Wygoda S, Ehrich JHH, Pape L, Konrad M, Rascher W, D\u00f6tsch J, M\u00fcller-Wiefel DE, Hoyer P, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, M\u00fcller GA, Weber M (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494\u2013501. https:\/\/doi.org\/10.1038\/ki.2011.407","journal-title":"Kidney Int"},{"key":"6696_CR20","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"O Gross","year":"2020","unstructured":"Gross O, T\u00f6nshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Zappel H, Hoyer P, Staude H, K\u00f6nig S, John U, Gellermann J, Hoppe B, Galiano M, Hoecker B, Ehren R, Lerch C, Kashtan CE, Harden M, Boeckhaus J, Friede T, German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators (2020) A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome. Kidney Int 97:1275\u20131286. https:\/\/doi.org\/10.1016\/j.kint.2019.12.015","journal-title":"Kidney Int"},{"key":"6696_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/ndt\/gfaa003","volume":"36","author":"SJ Schunk","year":"2021","unstructured":"Schunk SJ, Speer T, Petrakis I, Fliser D (2021) Dickkopf 3\u2014a novel biomarker of the \u2018kidney injury continuum. Nephrol Dial Transplant 36:761\u2013767. https:\/\/doi.org\/10.1093\/ndt\/gfaa003","journal-title":"Nephrol Dial Transplant"},{"key":"6696_CR22","doi-asserted-by":"publisher","first-page":"e84916","DOI":"10.1172\/jci.insight.84916","volume":"1","author":"G Federico","year":"2016","unstructured":"Federico G, Meister M, Mathow D, Heine GH, Moldenhauer G, Popovic ZV, Nordstr\u00f6m V, Kopp-Schneider A, Hielscher T, Nelson PJ, Schaefer F, Porubsky S, Fliser D, Arnold B, Gr\u00f6ne HJ (2016) Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. JCI Insight 1:e84916. https:\/\/doi.org\/10.1172\/jci.insight.84916","journal-title":"JCI Insight"},{"key":"6696_CR23","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1681\/ASN.2018040405","volume":"29","author":"S Zewinger","year":"2018","unstructured":"Zewinger S, Rauen T, Rudnicki M, Federico G, Wagner M, Triem S, Schunk SJ, Petrakis I, Schmit D, Wagenpfeil S, Heine GH, Mayer G, Floege J, Fliser D, Gr\u00f6ne HJ, Speer T (2018) Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J Am Soc Nephrol 29:2722. https:\/\/doi.org\/10.1681\/ASN.2018040405","journal-title":"J Am Soc Nephrol"},{"key":"6696_CR24","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1016\/j.ekir.2023.09.028","volume":"8","author":"H Rhode","year":"2023","unstructured":"Rhode H, L\u00fcse A, Tautkus B, Nabity M, John-Kroegel U, Weigel F, Dost A, Schitke J, Metzing O, B\u00f6ckhaus J, Rubel D, Kiess W, Gross O (2023) Urinary protein-biomarkers reliably indicate very early kidney damage in children with Alport syndrome independently of albuminuria and inflammation. Kidney Int Rep 8:2778\u20132793. https:\/\/doi.org\/10.1016\/j.ekir.2023.09.028","journal-title":"Kidney Int Rep"},{"key":"6696_CR25","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3390\/cells12091333","volume":"12","author":"J Boeckhaus","year":"2023","unstructured":"Boeckhaus J, Mohr L, Dihazi H, T\u00f6nshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Kettwig M, Staude H, K\u00f6nig S, John-Kroegel U, Gellermann J, Hoppe B, Galiano M, Haffner D, Rhode H, Gross O (2023) Ratio of urinary proteins to albumin excretion shifts substantially during progression of the podocytopathy Alport syndrome, and spot urine is a reliable method to detect these pathologic changes. Cells 12:1333. https:\/\/doi.org\/10.3390\/cells12091333","journal-title":"Cells"},{"key":"6696_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2012\/436046","volume":"2012","author":"O Gross","year":"2012","unstructured":"Gross O, Friede T, Hilgers R, G\u00f6rlitz A, Gav\u00e9nis K, Ahmed R, D\u00fcrr U (2012) Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: the double-blind, randomized, placebo-controlled, multicenter phase III early pro-tect Alport trial in pediatric patients. ISRN Pediatr 2012:436046. https:\/\/doi.org\/10.5402\/2012\/436046","journal-title":"ISRN Pediatr"},{"key":"6696_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ekir.2024.09.023","volume":"10","author":"M Dahmer-Heath","year":"2024","unstructured":"Dahmer-Heath M, Ger\u00df J, Fliser D, Liebau MC, Speer T, Telgmann AK, Burgmaier K, Pennekamp P, Pape L, Schaefer F, Konrad M, K\u00f6nig JC (2024) Urinary Dickkopf-3 reflects disease severity and predicts short-term kidney function decline in renal ciliopathies. Kidney Int Rep 10:197\u2013208. https:\/\/doi.org\/10.1016\/j.ekir.2024.09.023","journal-title":"Kidney Int Rep"},{"key":"6696_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.kint.2018.10.042","volume":"95","author":"N Ramkumar","year":"2019","unstructured":"Ramkumar N, Kohan DE (2019) The (pro)renin receptor: an emerging player in hypertension and metabolic syndrome. Kidney Int 95:1041\u20131052. https:\/\/doi.org\/10.1016\/j.kint.2018.10.042","journal-title":"Kidney Int"},{"key":"6696_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/MNH.0000000000000205","volume":"25","author":"L Zhou","year":"2016","unstructured":"Zhou L, Liu Y (2016) Wnt\/\u03b2-catenin signaling and renin\u2013angiotensin system in chronic kidney disease. Curr Opin Nephrol Hypertens 25:100. https:\/\/doi.org\/10.1097\/MNH.0000000000000205","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"6696_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrneph.2015.88","volume":"11","author":"L Zhou","year":"2015","unstructured":"Zhou L, Liu Y (2015) Wnt\/\u03b2-catenin signalling and podocyte dysfunction in proteinuric kidney disease. Nat Rev Nephrol 11:535\u2013545. https:\/\/doi.org\/10.1038\/nrneph.2015.88","journal-title":"Nat Rev Nephrol"},{"key":"6696_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1681\/ASN.2014010085","volume":"26","author":"L Zhou","year":"2015","unstructured":"Zhou L, Li Y, Hao S, Zhou D, Tan RJ, Nie J, Hou FF, Kahn M, Liu Y (2015) Multiple genes of the renin-angiotensin system are novel targets of Wnt\/\u03b2-catenin signaling. J Am Soc Nephrol 26:107. https:\/\/doi.org\/10.1681\/ASN.2014010085","journal-title":"J Am Soc Nephrol"},{"key":"6696_CR32","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/jcm12031034","volume":"12","author":"AKC Sch\u00e4fer","year":"2023","unstructured":"Sch\u00e4fer AKC, Pieper D, Dihazi H, Dihazi GH, L\u00fcders S, Koziolek MJ, Wallbach M (2023) Urinary Dickkopf-3 (DKK3) is associated with greater eGFR loss in patients with resistant hypertension. J Clin Med 12:1034. https:\/\/doi.org\/10.3390\/jcm12031034","journal-title":"J Clin Med"},{"key":"6696_CR33","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.kint.2021.06.029","volume":"100","author":"SJ Schunk","year":"2021","unstructured":"Schunk SJ, Beisswenger C, Ritzmann F, Herr C, Wagner M, Triem S, H\u00fctter G, Schmit D, Zewinger S, Sarakpi T, Honecker A, Mahadevan P, Boor P, Wagenpfeil S, J\u00f6rres R, Watz H, Welte T, Vogelmeier CF, Gr\u00f6ne HJ, Fliser D, Speer T, Bals R (2021) Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease. Kidney Int 100:1081\u20131091. https:\/\/doi.org\/10.1016\/j.kint.2021.06.029","journal-title":"Kidney Int"},{"key":"6696_CR34","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfac185","volume":"37","author":"J Gonz\u00e1lez","year":"2022","unstructured":"Gonz\u00e1lez J, Jatem E, Roig J, Valtierra N, Ostos E, Ab\u00f3 A, Santacana M, Garc\u00eda A, Segarra A (2022) Usefulness of urinary biomarkers to estimate the interstitial fibrosis surface in diabetic nephropathy with normal kidney function. Nephrol Dial Transplant 37:2102\u20132110. https:\/\/doi.org\/10.1093\/ndt\/gfac185","journal-title":"Nephrol Dial Transplant"},{"key":"6696_CR35","doi-asserted-by":"publisher","first-page":"885018","DOI":"10.3389\/fmed.2022.885018","volume":"9","author":"A Schuster","year":"2022","unstructured":"Schuster A, Steines L, M\u00fcller K, Zeman F, Findeisen P, Banas B, Bergler T (2022) Dickkopf 3\u2014a new indicator for the deterioration of allograft function after kidney transplantation. Front Med 9:885018. https:\/\/doi.org\/10.3389\/fmed.2022.885018","journal-title":"Front Med"},{"key":"6696_CR36","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3390\/jcm11112977","volume":"11","author":"S Sciascia","year":"2022","unstructured":"Sciascia S, Barinotti A, Radin M, Cecchi I, Menegatti E, Terzolo E, Rossi D, Baldovino S, Fenoglio R, Roccatello D (2022) Dickkopf Homolog 3 (DKK3) as a prognostic marker in lupus nephritis: a prospective monocentric experience. J Clin Med 11:2977. https:\/\/doi.org\/10.3390\/jcm11112977","journal-title":"J Clin Med"},{"key":"6696_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.ackd.2016.11.011","volume":"24","author":"HW Schnaper","year":"2017","unstructured":"Schnaper HW (2017) The tubulointerstitial pathophysiology of progressive kidney disease. Adv Chronic Kidney Dis 24:107\u2013116. https:\/\/doi.org\/10.1053\/j.ackd.2016.11.011","journal-title":"Adv Chronic Kidney Dis"},{"key":"6696_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.kint.2017.09.033","volume":"93","author":"BC Liu","year":"2018","unstructured":"Liu BC, Tang TT, Lv LL, Lan HY (2018) Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int 93:568\u2013579. https:\/\/doi.org\/10.1016\/j.kint.2017.09.033","journal-title":"Kidney Int"},{"key":"6696_CR39","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2015010006","volume":"26","author":"MA Venkatachalam","year":"2015","unstructured":"Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK (2015) Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol 26:1765. https:\/\/doi.org\/10.1681\/ASN.2015010006","journal-title":"J Am Soc Nephrol"},{"key":"6696_CR40","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00424-017-2018-7","volume":"469","author":"EF Gr\u00f6ne","year":"2017","unstructured":"Gr\u00f6ne EF, Federico G, Nelson PJ, Arnold B, Gr\u00f6ne HJ (2017) The hormetic functions of Wnt pathways in tubular injury. Pflugers Arch 469:899\u2013906. https:\/\/doi.org\/10.1007\/s00424-017-2018-7","journal-title":"Pfl\u00fcg Arch - Eur J Physiol"},{"key":"6696_CR41","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.1038\/sj.onc.1210054","volume":"25","author":"C Niehrs","year":"2006","unstructured":"Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:7469\u20137481. https:\/\/doi.org\/10.1038\/sj.onc.1210054","journal-title":"Oncogene"},{"key":"6696_CR42","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1681\/ASN.2008101086","volume":"20","author":"DR Abrahamson","year":"2009","unstructured":"Abrahamson DR, Hudson BG, Stroganova L, Borza DB, John PLS (2009) Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol 20:1471\u20131479. https:\/\/doi.org\/10.1681\/ASN.2008101086","journal-title":"J Am Soc Nephrol"},{"key":"6696_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration\u00a0(2019) Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol 7:128\u2013139. https:\/\/doi.org\/10.1016\/S2213-8587(18)30314-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6696_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s44162-023-00022-x","volume":"2","author":"H Pearce","year":"2023","unstructured":"Pearce H, Mabillard H (2023) Finerenone and other future therapeutic options for Alport syndrome. J Rare Dis 2:18. https:\/\/doi.org\/10.1007\/s44162-023-00022-x","journal-title":"J Rare Dis"},{"key":"6696_CR45","doi-asserted-by":"publisher","unstructured":"Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R, Gerst C, Duerr U, Walker F, Tostmann R, Helm J, Asendorf T, Friede T (2024) Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrol Dial Transplant Aug 9:gfae180. https:\/\/doi.org\/10.1093\/ndt\/gfae180","DOI":"10.1093\/ndt\/gfae180"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06696-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:02:51Z","timestamp":1751029371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06696-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6696"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06696-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}